Peptide Therapy 101: Can BPC 157 & Thymosin Beta 4 Accelerate Ortho Recovery? FDA's Overreach on Compounded Peptides BPC 157 Benefits: Heal & Thrive in 2025 Peptide Therapy for Inflammation: A New Solution BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law